HOUSTON--(BUSINESS WIRE)--Apr. 18, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company, and its collaborating investigators at Leiden University Medical Center (LUMC), have been selected for a late-breaking poster presentation of a T cell receptor (TCR) product candidate containing the proprietary MyD88/CD40 activation switch (Go-TCR™) at the AACR 2016 Annual Meeting. The conference will take place in New Orleans from April 16-20, 2016.

The presentation, titled “Go-TCR: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells, Increasing Anti-Tumor Efficacy” will highlight preclinical data demonstrating that its novel “go” switch can augment activation and expansion of TCR-engineered T cells while sensitizing tumors to T cells via cytokine-induced MHC class I upregulation.

The poster will be available in the Events & Presentations section of the Bellicum website at the time of the presentation.

Presentation Details

• Abstract Number: LB-084
• Presentation Title: “Go-TCR: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T cells, Increasing Anti-Tumor Efficacy”
• Presentation Date: Monday, April 18, 2016
• Presentation Time: 8:00 a.m. -12:00 p.m. CDT

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

Forward-Looking Statement

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," “designed,” "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to iMC, CAR T, TCRs or Go-TCRs; the effectiveness of iMC, CAR T, TCRs or Go-TCRs, their possible range of application and potential curative effects and safety in the treatment of diseases; and the potential applications and effectiveness of our product candidates, including as compared to other treatment options and competitive therapies. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2015. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160418005059/en/

Source: Bellicum Pharmaceuticals, Inc.

Investors:
Bellicum Pharmaceutical
Alan Musso, CFO, 832-384-1116
amusso@bellicum.com
or
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com